Press Releases Archives

Somite Therapeutics and OmniaBio Inc. Announce Collaboration to Advance Somite’s Cell Therapy Flagship Program

CDMO collaboration propels cell replacement therapy targeting Duchenne muscular dystrophy forward, with consequences for the role of AI in cell therapy. September 9, 2024 (BOSTON, MA and HAMILTON, Ontario) – Somite Therapeutics, a tech-bio company harnessing big data and AI to pioneer novel cell replacement therapies, and OmniaBio Inc., a technology-driven cell and gene therapy CDMO […]

Somite Therapeutics and OmniaBio Inc. Announce Collaboration to Advance Somite’s Cell Therapy Flagship Program Read More »

LineaBio launches off-the-shelf GMP iPSC lines to accelerate iPSC-based cell therapies

CCRM and OmniaBio spin-off provides high-quality iPSC lines that expedite time to GMP by 12 months and reduce cell line development costs by up to 60%. July 30, 2024 (Toronto, Ontario) – LineaBio, a cell line company, today announced the launch of its catalogue of off-the-shelf induced pluripotent stem cell (iPSC) lines. The off-the-shelf iPSC

LineaBio launches off-the-shelf GMP iPSC lines to accelerate iPSC-based cell therapies Read More »

OmniaBio announces Kenneth L. Harris as Chief Strategy Officer and Head of AI

June 12, 2024 (Hamilton, Ontario) – OmniaBio Inc. is pleased to announce the appointment of Kenneth (Ken) L. Harris as its Chief Strategy Officer and Head of Artificial Intelligence (AI), strengthening its mandate of bringing maturity to cell and gene therapy (CGT) through focused CGT expertise in contract development and manufacturing. Harris, a seasoned executive

OmniaBio announces Kenneth L. Harris as Chief Strategy Officer and Head of AI Read More »

NGen Unveils $86.7 Million in New Advanced Manufacturing Projects at N3 Summit

15 New projects underway to build world leading advanced manufacturing capabilities in Canada. TORONTO, ON, February 8, 2024 – NGen has announced over $32.3 million in Global Innovation Cluster funding for 15 new advanced manufacturing projects. With industry contributions of $54.4 million, the 15 projects are valued at a total of $86.7 million. The announcement

NGen Unveils $86.7 Million in New Advanced Manufacturing Projects at N3 Summit Read More »

Advanced Cell Therapy Manufacturing Initiative To Be Established in Brisbane

CCRM Australia, with its Canadian partners OmniaBio Inc. and Toronto-based CCRM, has signed a Letter of Intent with The University of Queensland to establish the Advanced Cell Therapy Manufacturing Initiative (ACTMI)…

Advanced Cell Therapy Manufacturing Initiative To Be Established in Brisbane Read More »

CATTI opens a cell and gene therapy training centre of excellence at the University of Guelph

The Canadian Advanced Therapies Training Institute (CATTI) Inc. has launched its first in-person training site at the University of Guelph…

CATTI opens a cell and gene therapy training centre of excellence at the University of Guelph Read More »

Catamaran Bio selects OmniaBio as partner to develop and manufacture allogeneic CAR-NK cell therapies

Catamaran Bio Inc., a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, and OmniaBio Inc., a CDMO focused on…

Catamaran Bio selects OmniaBio as partner to develop and manufacture allogeneic CAR-NK cell therapies Read More »

OmniaBio expands manufacturing footprint with second Hamilton location

OmniaBio Inc. has expanded its footprint by adding a new process and analytical development lab space at the McMaster University Medical Centre (MUMC)…

OmniaBio expands manufacturing footprint with second Hamilton location Read More »

Avectas, CCRM and OmniaBio Expand their Collaboration to Accelerate the Manufacture of Edited iPSCs Using SOLUPORE® Technology

Avectas, a cell
engineering technology business and CCRM, with its subsidiary OmniaBio Inc., a CDMO
that enables the development of cell therapies and…

Avectas, CCRM and OmniaBio Expand their Collaboration to Accelerate the Manufacture of Edited iPSCs Using SOLUPORE® Technology Read More »

Resolution Therapeutics and CCRM sign collaboration agreement, with work to be executed at OmniaBio

Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapies to treat advanced liver…

Resolution Therapeutics and CCRM sign collaboration agreement, with work to be executed at OmniaBio Read More »